Evidence map›Paper›PMID 42140912›Full record

ArticleNature communications2026

PromoterAtlas: decoding regulatory sequences across Gammaproteobacteria using a transformer model.

Lucas Coppens, Rodrigo Ledesma-Amaro

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lucas CoppensLondon Biofoundry, Translation and Innovation Hub, Imperial College White City Campus, London, UK. l.coppens20@imperial.ac.uk.ORCID http://orcid.org/0000-0002-2873-0369
Rodrigo Ledesma-AmaroDepartment of Bioengineering, Imperial College London, London, UK. r.ledesma-amaro@imperial.ac.uk.ORCID http://orcid.org/0000-0003-2631-5898

Funding

RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/Y008510/1
6 · The paper itself

Abstract

Recent advances in deep learning, particularly transformer architectures, have improved computational approaches for biological sequence analysis. Despite these advances, computational models for bacterial promoter prediction have remained limited by small datasets, species-specific training, and binary classification approaches rather than comprehensive annotation frameworks. We present PromoterAtlas, a 1.8 M parameter transformer model trained on 9 M regulatory sequences from 3371 gammaproteobacterial species. The model demonstrates recognition of various regulatory elements across different species, including ribosomal binding sites, various types of bacterial promoters, transcription factor binding sites, and terminators. Using this model, we developed a whole-genome promoter annotation tool for Gammaproteobacteria, with various levels of validation that support the predictions of promoters associated with different sigma (σ) factors. Furthermore, we show that the model embeddings reflect cross-species evolutionary relationships, clustering promoters by σ factor identity rather than species-specific sequence features. Finally, we show that model embeddings encode regulatory sequence information that enables effective prediction of transcription and translation levels. PromoterAtlas can contribute to our understanding of and ability to engineer bacterial regulatory sequences with potential applications in bacterial biology, synthetic biology, and comparative genomics.

Indexed as

Computational BiologyGammaproteobacteriaPromoter Regions, GeneticRegulatory Sequences, Nucleic AcidBacterial ProteinsBinding SitesGene Expression Regulation, BacterialGenome, BacterialSigma FactorBacterial ProteinsSigma Factor

Identifiers

PMID42140912
PMCPMC13377108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.